Skip to main content
Kenneth Murray, MD, Neurology, Cullman, AL

KennethRMurrayMD

Neurology Cullman, AL

Sleep Medicine

Assistant Clinical Professor of Neurology, SUNY Buffalo

Are you Dr. Murray?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

  • Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
    You already have 72 invites waiting!
  • Read the latest clinical news, personalized to your specialty.

Claim this profile

Not you? Find your profile

  • Office

    1890 AL Highway 157
    Ste 102
    Cullman, AL 35058
    Phone+1 256-903-0300
    Fax+1 256-801-7893

Summary

  • Dr. Kenneth Murray, MD is a board certified neurologist in Cullman, Alabama. He is currently licensed to practice medicine in Alabama, Nebraska, and Texas. He is affiliated with Cullman Regional Medical Center and is an Assistant Clinical Professor of Neurology at SUNY Buffalo.

Education & Training

  • University at Buffalo
    University at BuffaloResidency, Neurology, 1983 - 1987
  • Jacobs School of Medicine and Biomedical Sciences at the University at Buffalo
    Jacobs School of Medicine and Biomedical Sciences at the University at BuffaloClass of 1983

Certifications & Licensure

  • NY State Medical License
    NY State Medical License 1984 - 2025
  • AL State Medical License
    AL State Medical License 2023 - 2024
  • NE State Medical License
    NE State Medical License 2021 - 2024
  • TX State Medical License
    TX State Medical License 1987 - 1988
  • American Board of Psychiatry and Neurology Neurology

Awards, Honors, & Recognition

  • Buffalo Spree Magazine Castle Connolly, 2011-2014
  • CMS Meaningful Use Stage 1 Certification eClinicalWorks EHR, eClinicalWorks LLC, 2012-2013

Press Mentions

  • Sage Therapeutics and Biogen Present Further Analyses from Phase 3 SKYLARK Study of Zuranolone in Postpartum Depression at the European College of Neuropsychopharmacology (ECNP) Congress
    Sage Therapeutics and Biogen Present Further Analyses from Phase 3 SKYLARK Study of Zuranolone in Postpartum Depression at the European College of Neuropsychopharmacology (ECNP) CongressOctober 17th, 2022
  • Sage Therapeutics and Biogen Announce That the Phase 3 SKYLARK Study of Zuranolone in Postpartum Depression Met Its Primary and All Key Secondary Endpoints
    Sage Therapeutics and Biogen Announce That the Phase 3 SKYLARK Study of Zuranolone in Postpartum Depression Met Its Primary and All Key Secondary EndpointsJune 1st, 2022
  • How Doctors Die
    How Doctors DieDecember 13th, 2018

Professional Memberships